SLN
Silence Therapeutics plc
SLN
Silence Therapeutics plc
Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its prima
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and str